ReNeuron Group plc Directorate Change (7669H)
06 Agosto 2021 - 01:00AM
UK Regulatory
TIDMRENE
RNS Number : 7669H
ReNeuron Group plc
06 August 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Directorate Change
Appointment of Chief Financial Officer
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces the appointment
of Catherine Isted, ACMA, who will be joining the Board as Chief
Financial Officer effective 11 October, 2021.
Ms. Isted is an experienced strategic finance professional and
chartered accountant with 23 years' experience across the
Healthcare industry. This includes 12 years at partner level in two
leading Healthcare banking teams undertaking multiple Initial
Public Offerings and follow-on fundraisings. Within the Healthcare
industry, Ms. Isted has also held various in-house financial and
strategic roles spanning Corporate Development, Investor Relations
(IR) and Financial Planning and Analysis.
She is joining ReNeuron from Oxford Biomedica plc, a global
leading cell and gene therapy company, where Ms. Isted sits as part
of the finance leadership team heading up the Corporate Development
and IR. During her time working with the Group, as well as
supporting potential board level strategic opportunities, she has
been instrumental in raising in excess of GBP110 million for the
Group over 3 tranches, transforming and internationalising the
shareholder base, seeing the company grow 800% and enter the
FTSE250. Ms. Isted has also held research analyst and equity sales
positions in the Healthcare teams at Morgan Stanley, ABN AMRO,
Nomura and Peel Hunt.
Ms. Isted holds a 1(st) Class chemistry degree along with
experience as a bench scientist, before moving into finance and
training as an accountant at Merck. Ms Isted's career path has
provided a highly differentiated and strategic view on the
healthcare industry and will be invaluable to ReNeuron during a
dynamic time for the Company.
Ian Ross , Chairman, commented: "Catherine has an excellent
knowledge of the healthcare sector and is highly skilled in equity
capital markets, M&A and strategic business development. She
will be a fantastic addition to the ReNeuron Board and I am
thoroughly looking forward to working alongside her and welcoming
her to the ReNeuron Board ."
Olav Hellebø , CEO, commented: "I am delighted to welcome
Catherine to the ReNeuron management team . Her extensive financial
markets experience as well as her background as a healthcare
analyst will be incredibly valuable going forward as the Company
continues to grow."
Catherine Isted, incoming Chief Financial Officer commented: "I
am delighted to be joining ReNeuron at what I think is an exciting
time in the company's evolution, not only for the Groups lead stem
cell programme in Retinitis Pigmentosa but also for their
proprietary Exosomes and induced pluripotent stem cell (iPSC)
platform technologies where there is growing excitement in the
healthcare industry around their significant potential in a
multiple of therapeutic areas. I look forward to working with the
whole team and Board at ReNeuron to help realise the opportunity
for the company in these leading fields of science."
Disclosures in accordance with the AIM Rules
Catherine Ann Isted , 46, is, or has been, a director or partner
of the following companies or partnerships during the past five
years:
Current Partnerships and Directorships:
Horne Grange Farm
Prior Partnerships and Directorships:
Peel Hunt LLP
Ms. Isted owns no shares in ReNeuron.
There are no further disclosures required in accordance with AIM
Rule 17 and Schedule Two paragraph (g) of the AIM Rules for
Companies.
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments for disease with significant unmet
needs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the central nervous system and other disorders. The
Company also has the ability through its conditionally immortalised
induced pluripotent stem cell (iPSC) platform to make allogeneic
tissue cells of choice; in-house programmes are currently focused
on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOABLGDICBGDGBU
(END) Dow Jones Newswires
August 06, 2021 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024